Marketing Efforts Pay Off As Admedus Ups CardioCel Centers By 50%
Executive Summary
A new deal with an aortic ring manufacturer, a change of chairman, a hike in the number of centers using its cardiovascular bioscaffold and plans to develop an aortic valve repair scaffold have attracted much attention to Admedus in the past six months. The Australian company’s immunotherapies platform is also advancing well, says CEO Lee Rodne.
You may also be interested in...
New Future For Admedus Immunotherapies? – Not Yet
Admedus is mulling over the future of its vaccines business.
How To Restructure: Admedus Opts For A Restart
Admedus and its product mix was an unfolding success story – and still is, due to a restructuring of activities and a resetting of aims that have ensured the Australia-US tissue engineering company does not miss out on the opportunities it has crafted for itself. Chairman and interim CEO Wayne Paterson explains what changes were required and why.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.